Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2014

View Archived Issues

Novel antiviral drugs demonstrate efficacy against diverse RNA and DNA viral pathogens

Update on phase I trial of AG-221, a potent IDH2 mutant protein inhibitor

Fibrocell and Intrexon's epidermolysis bullosa cell therapy receives U.S. orphan drug status

Novel agents for parasitic diseases designed by IRM and Novartis

[18F]-GP1: a potential a PET tracer for thrombi in humans

PSMA ligand evaluated in patients for the diagnosis of prostate cancer

Novel PIKfyve inhibitor described by Astellas scientists

University of Cape Town discloses agents for tuberculosis

Biofordrug designs novel 5-HT7 receptor ligands

DiscoveryBiomed presents novel CFTR correctors for cystic fibrosis

GlaxoSmithKline divulges new DGAT1 inhibitors

New agents for allergic diseases designed at GlaxoSmithKline

New Omega-3 fatty acid analogues disclosed by the University of Sydney

Phase I data reported for Themis Bioscience's vaccine against Chikungunya fever

Aastom Biosciences outlines strategic plans for cell therapy and regenerative medicine business

Torii Pharmaceutical reports results from Japanese trials of house dust mite SLIT tablet

Rucaparib enters phase II trial in BRCA-mutant pancreatic cancer

Medtronic to acquire Covidien

FDA grants orphan drug designation to AG-221 for AML

Dainippon Sumitomo Pharma closes further enrollment in phase III colorectal cancer study

FDA and EMA accept applications for AbbVie's HCV regimen

Kringle initiates Japanese study of rhHGF in acute spinal cord injury

BL-8040 to be evaluated for stem cell mobilization in phase I trial

Vedolizumab enters U.S. market for ulcerative colitis and Crohn's disease

Convergence reports positive phase II data for sodium channel blocker analgesic

Gilead Sciences reports data from phase III study of ledipasvir/sofosbuvir in Japanese patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...